Press release - 2013 first-half revenues
Bezons, July 25th, 2013; 5:45 pm
2013 first-half revenues: €7.8 million
Bezons, July 25th, 2013 - 5:45 pm - RIBER, the global leader for molecular beam epitaxy (MBE), recorded €7.8 million in revenues for the first half of 2013. Revenues for the second quarter of 2013 came to €5.1 million, compared with €3.2 million for the second quarter of 2012. The order book at June 30th, 2013 represented €11.7 million (€12.1 million at December 31st, 2012).
| €'000,000 | H1 2013 | H1 2012 | Change |
| Systems | 4.8 | 6.4 | -26% |
| Services and accessories | 2.6 | 2.2 | +14% |
| Cells and sources | 0.5 | 0.8 | -29% |
| Total reported revenues | 7.8 | 9.4 | -16% |
| Systems order book | 10.2 | 18.8 | -46% |
| Services and accessories order book | 1.3 | 1.7 | -24% |
| Cells and sources order book | 0.2 | 1.0 | -81% |
| Total order book | 11.7 | 21.5 | -46% |
Business developments
During the first half of the year, the company invoiced five MBE machines, compared with six in the first half of 2012 (including one production machine).
Sales of services and accessories are up 14%. Despite the slowdown in supplies of services to industrial customers, RIBER is benefiting from the development of sales to research laboratories, reflecting the impact of the commercial action plan rolled out in 2012.
Sales of evaporation sources and effusion cells are being affected by the current lack of deliveries of equipment for the production of OLED flat screens or thin-film solar cells. RIBER is maintaining a major research effort on these structurally buoyant markets.
At June 30th, 2013, the breakdown of RIBER's sales was as follows: Asia (45%), North America (31%) and Europe (24%).
Outlook
During the second quarter of 2013, RIBER booked an order for an MBE system in the United States. In view of an order book at June 30th, 2013 amounting to €11.7 million, including 12 systems (with five ordered during the first half of 2013) and the business prospects, a significant recovery in revenues is expected in the second half of 2013. Furthermore, an order has been received in July for a system to be delivered in Japan.
First-half earnings and the outlook for the full year will be published on September 27th, 2013 before start of trading.
About RIBER:
Riber designs and produces molecular beam epitaxy (MBE) systems as well as evaporation sources and cells for the semiconductor industry. This high-technology equipment is essential for the manufacturing of compound semiconductor materials and new materials that are used in numerous consumer applications, such as new information technologies, OLED flat screens and new generation solar cells.
Riber recorded €27.4 million in revenues in 2012 and employs 111 people. The company is ISO9001 certified. Riber is listed on NYSE-Euronext Paris, Compartment "C", and is part of the CAC Small, CAC Mid & Small, CAC Technology and CAC T. HARD. & EQ indices. Riber is one of the best-rated companies in the Gaïa-index, the leading SRI index for French mid-caps.
ISIN: FR0000075954 - RIB
Reuters: RIBE.PA
Bloomberg: RIB: FP
OSEO-approved innovative company
| RIBER Olivier Handschumacher tel: +33 1 39 96 65 00 invest@riber.com | CALYPTUS Cyril Combe tel: +33 1 53 65 68 68 cyril.combe@calyptus.net |
